Savara Inc
NASDAQ:SVRA
Savara Inc
Common Stock
Savara Inc
Common Stock Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Common Stock | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Savara Inc
NASDAQ:SVRA
|
Common Stock
$173k
|
CAGR 3-Years
20%
|
CAGR 5-Years
12%
|
CAGR 10-Years
-1%
|
|
|
Abbvie Inc
NYSE:ABBV
|
Common Stock
$18m
|
CAGR 3-Years
0%
|
CAGR 5-Years
0%
|
CAGR 10-Years
1%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Common Stock
$1m
|
CAGR 3-Years
0%
|
CAGR 5-Years
0%
|
CAGR 10-Years
-7%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Common Stock
$33.5B
|
CAGR 3-Years
1%
|
CAGR 5-Years
1%
|
CAGR 10-Years
1%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Common Stock
$2.6m
|
CAGR 3-Years
-5%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
3%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Common Stock
$101.8k
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Savara Inc
Glance View
Savara, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. The company is headquartered in Austin, Texas and currently employs 22 full-time employees. The company went IPO on 2001-06-25. The firm is focused on rare respiratory diseases. The Company’s lead program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase III development for autoimmune pulmonary alveolar proteinosis (aPAP). Molgramostim an inhaled formulation of recombinant human GM-CSF, is being developed for the treatment of aPAP. Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by the build-up of surfactant in the alveoli or air sacs of the lungs.
See Also
What is Savara Inc's Common Stock?
Common Stock
173k
USD
Based on the financial report for Dec 31, 2024, Savara Inc's Common Stock amounts to 173k USD.
What is Savara Inc's Common Stock growth rate?
Common Stock CAGR 10Y
-1%
Over the last year, the Common Stock growth was 24%. The average annual Common Stock growth rates for Savara Inc have been 20% over the past three years , 12% over the past five years , and -1% over the past ten years .
You don't have any saved screeners yet